Table 3.
Baseline characteristics of MZL patients treated with different anti-CD20 monoclonal antibodies.
| Characteristics | R±chemotherapy (n=111) |
G±chemotherapy (n=36) |
χ2 | P | ||
|---|---|---|---|---|---|---|
| Sex | 0.055 | 0.814 | ||||
| Male | 58 (52.3%) | 18 (50.0%) | ||||
| Female | 53 (47.7%) | 18 (50.0%) | ||||
| Age | 0.055 | 0.814 | ||||
| <60 years | 58 (52.3%) | 18 (50.0%) | ||||
| ≥60 years | 53 (47.7%) | 18 (50.0%) | ||||
| Ann Arbor stage | 0.625 | 0.429 | ||||
| I-II | 42 (37.8%) | 11 (30.6%) | ||||
| III-IV | 69 (62.2%) | 25 (69.4%) | ||||
| MZL-IPI | 0.634 | 0.811 | ||||
| 0 | 41 (36.9%) | 11 (30.6%) | ||||
| 1-2 | 60 (54.1%) | 21 (58.3%) | ||||
| 3-5 | 10 (9.0%) | 4 (11.1%) | ||||
| B symptoms | 3.244 | 0.072 | ||||
| no | 90 (81.1%) | 24 (66.7%) | ||||
| yes | 21 (18.9%) | 12 (33.3%) | ||||
| ECOG | 0.006 | 0.940 | ||||
| 0-1 | 87 (78.4%) | 28 (77.8%) | ||||
| ≥2 | 24 (21.6%) | 8 (22.2%) | ||||
| High tumor burden | 8.611 | 0.003 | ||||
| no | 71 (64.0%) | 13 (36.1%) | ||||
| yes | 40 (36.0%) | 23 (63.9%) | ||||
| INV-assessed response | 4.195 | 0.128 | ||||
| CR | 62 (55.9%) | 21 (58.3%) | ||||
| PR | 38 (34.2%) | 15 (41.7%) | ||||
| SD/PD | 11 (9.9%) | 0 (0) | ||||
MZL, marginal zone lymphoma; MZL-IPI, MZL-international prognostic index; ECOG, Eastern Cooperative Oncology Group; G, obinutuzumab; R, rituximab; INV, investigator; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.